Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Adult HBV Vaccination: Identifying Individuals at Risk for Reduced Seroprotection

Listen to expert discussion on identifying adults at risk for reduced HBV seroprotection and applying current HBV vaccine recommendations in special populations.
Robert G. Gish, MD
Released: May 5, 2022

In this episode, learn about the importance of identifying adults at risk for reduced hepatitis B virus (HBV) seroprotection and applying current HBV vaccine recommendations in special populations. Listen as Robert G. Gish, MD, discusses key information on the identification and evaluation of patients who have chronic health conditions and therefore may be at risk for nonresponse to available vaccines.

Information on this Educational Activity

Faculty

Robert G. Gish, MD

Professor of Medicine
Loma Linda University
Loma Linda, California
Adjunct Professor of Medicine
Nevada School of Medicine
Las Vega, Nevada
Clinical Professor
University of Nevada Reno School of Medicine
Clinical Professor
University of California Skaggs School of Pharmacy and Pharmaceutical Sciences
San Diego, California
Medical Director

Hepatitis B Foundation
Washington, DC

Robert G. Gish, MD, has disclosed that he has received funds for research support from Gilead Sciences; has received consulting fees from Abbott, AbbVie, Altimunne, Antios, Arrowhead, Dynavax, Eiger, Eisai, Enyo, Fibronostics, Fujifilm/Wako, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, Helios, Hepatx, HepQuant, Intercept, Janssen, Merck, Perspectum, Pfizer, Quest, Sonic Incytes, and Topography Health, and Venatorx; has served on advisory boards for AbbVie, Antios, Dynavax, Enyo, Genentech, Genlantis, Gilead, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer and Prodigy; serves on current clinical trials alliance for Topography Health; and has served on data and safety monitoring boards for Altimmune, Arrowhead, CymaBay, and Durect; serves on speakers bureaus for AbbVie, BMS, Eisai, Genentech, Gilead Sciences, and Intercept; and has stock options with Eiger, Genlantis, HepQuant, AngioCrine, HepaTx.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
VBI Vaccines Inc.

Related Content

Drs. Kosh Agarwal and Graham R. Foster discuss linkage to care for patients with HDV, from Clinical Care Options (CCO)

Kosh Agarwal, MD Graham R. Foster, FRCP, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: June 30, 2022 Expired: June 29, 2023

Patient perspectives and key action items to address in clinical settings to reduce HBV care barriers in the United States, from Clinical Care Options (CCO)

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Jennifer Wild, MS, BSN, RN, OCN Released: June 22, 2022

Dr Norah Terrault: missed opportunities for hepatitis delta virus (HDV) testing and how to overcome them, from Clinical Care Options (CCO)

Norah Terrault Headshot Norah Terrault, MD, MPH Released: May 18, 2022

Compare current HBV vaccines and learn the best immunization practices for routine vaccination, including in special situations, from Clinical Care Options (CCO)

Robert G. Gish, MD Released: May 9, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings